Please login to the form below

Not currently logged in
Email:
Password:

US pharma market

This page shows the latest US pharma market news and features for those working in and with pharma, biotech and healthcare.

EMA to consider coronavirus' impact on EU medicines supply

EMA to consider coronavirus' impact on EU medicines supply

US pharma market. ... According to Reuters, around 88% of APIs used in drugs for the US market were manufactured overseas in 2018, with around 14% in that year produced in China.

Latest news

  • Pharma’s R&D productivity sinks to a new low Pharma’s R&D productivity sinks to a new low

    It’s no secret that smaller pharma and biotech firms have been able to achieve greater productivity compared to big pharma. ... all-important US market.

  • Belgium's Ablynx enters the US market Belgium's Ablynx enters the US market

    Belgium biopharmaceutical company Ablynx has established a beachhead in the US, setting up a new subsidiary for that market. ... Prior to that he held a number of senior commercial with Sepracor, prior to its acquisition by Dainippon Sumitomo Pharma (DSP)

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved it will also be sold by Vifor Pharma in the US dialysis market. ... Pfizer in a statement.  Amgen reported Epogen sales of $1.3bn last year – all from the US market – while Procrit earned $1.1bn for J&J, including $767m from the US.

  • US cuts at Boehringer hit sales force hardest US cuts at Boehringer hit sales force hardest

    Its Prescription Medicines Business Unit will be responsible for the subsequent 'highly market-oriented development' of products. ... The US pharma industry has been hard hit in the last year, and the company is not alone in making cutbacks.

  • Iressa set for US market return after FDA approval Iressa set for US market return after FDA approval

    gene mutation, setting the scene for its return to the US market after an absence of four years. ... trial. AZ eventually took it off the US market in 2011, before the FDA revoked its accelerated approval status a year later.

More from news
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • The US celebrates five years of biosimilars on the market – a look to the past, present and future The US celebrates five years of biosimilars on the market – a look to the past, present and future

    Yet unlike generic medicines, which have delivered substantial savings in the small molecule market, the success of biosimilars in the US has been mixed. ... Moreover, increasing the number of available biosimilars on the US market can improve access to

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    But for the most part, the feast-and-famine cycle of the US market has been viewed as a success. ... And finally there is the issue of interchangeability. In a move unique to the US market, the BPCI created two pathways for approval: an abbreviated one

  • Making digital health personal Making digital health personal

    Progress tracking: A case study. This case study looks at a native app developed in the US market for a local pharma client that allows patients to plan their medication schedule; ... Digital inspiration for pharma on mobile, social media, strategy, best

  • The pharma business environment in the US The pharma business environment in the US

    How companies respond to these changes will determine the future of the US pharma market. ... Recognising the extensive changes and their implications, CPhI and InformEx conducted extensive research of the US pharma market.

  • Positive prospects for pharma in Latin America Positive prospects for pharma in Latin America

    policies. However, there are deficit problems and inflation is expected to remain high, which impacts on the pharma market. ... ratified a Free Trade Agreement with the US, which has boosted the pharma market, dominated by national companies and doing

More from intelligence
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Conversis Medical names Mark Hooper global director Conversis Medical names Mark Hooper global director

    Dr Hooper has worked in the pharma services field for the past 13 years and has experience in both the contract research organisation (CRO) and contract manufacturing organisation (CMO) environments. ... Mark's deep understanding of the pharma market

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Creative effectiveness: how to achieve tangible results

    Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market. ... Advertising provides us with so much opportunity to create, to inspire,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics